So glad to be here and relieved to see you as the
Post# of 5066
I had talked to a woman a few weeks back that now works for a private bio and was once employed by avi now srpt. We talked about BMSN and i asked her what things might the FDA be interested in (or hung-up on) even with a great application. One thing she mentioned was the location of where the drug mixes with patient's bio. She asked me if ever the patient's fat (or whatever is extracted) will be taken physically from that lab or building to another location and then physically returned to that location. I could not answer. But she said this movement in trials causes FDA to pause and ask more questions. What are your thoughts? I hope this question and statement is clear. I apologize for my lack of understanding in it.